​

XTL Biopharmaceuticals Ownership | Who Owns XTL Biopharmaceuticals?

OverviewChart

XTL Biopharmaceuticals Ownership Summary

XTL Biopharmaceuticals is owned by 0.03% institutional investors, 41.29% insiders, and 58.67% retail investors. Morgan stanley is the largest institutional shareholder, holding 0.61% of XTLB shares. Fidelity Nasdaq Composite Index is the top mutual fund, with 0.10% of its assets in XTL Biopharmaceuticals shares.

XTLB Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockXTL Biopharmaceuticals0.03%41.29%58.67%
SectorHealthcare Stocks 487.91%11.08%-398.99%
IndustryBiotech Stocks 307.10%11.11%-218.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Morgan stanley33.15K0.61%$80.56K
Citadel advisors15.44K0.28%$36.58K
Noked israel198.89K0.03%$227.00K
Rhumbline advisers10.95K0.00%$22.56K
Bnp paribas arbitrage, snc---
Ubs group---

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Noked israel198.89K0.04%$227.00K
Rhumbline advisers10.95K-$22.56K
Bnp paribas arbitrage, snc---
Ubs group---
Citadel advisors15.44K-$36.58K
Morgan stanley33.15K-$80.56K

Top Buyers

HolderShares% AssetsChange
Rhumbline advisers10.95K-4.43K
Citadel advisors15.44K-1.80K
Noked israel198.89K0.04%-
Bnp paribas arbitrage, snc---300.00
Morgan stanley33.15K--6.02K

Top Sellers

HolderShares% AssetsChange
Ubs group---6.95K
Morgan stanley33.15K--6.02K
Bnp paribas arbitrage, snc---300.00
Noked israel198.89K0.04%-
Citadel advisors15.44K-1.80K

Sold Out

HolderChange
Bnp paribas arbitrage, snc-300.00
Ubs group-6.95K

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20254-228,496-7.98%-1633.99%2100.00%1-
Mar 31, 2025433.33%248,3048.81%-2596.90%1-1-
Dec 31, 20243-228,193-1.58%-0.23%1-1-
Sep 30, 20243-25.00%231,858-8.38%419.73%1-50.00%1-
Jun 30, 20244-20.00%253,058-2.27%420.57%2-1-

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Fidelity Nasdaq Composite Index8.90K0.10%-

Recent Insider Transactions

DateNameRoleActivityValue
Nov 18, 2008EDELMAN JOSEPH-Sell$412.02K
Nov 19, 2008EDELMAN JOSEPH-Sell$1.47M
Nov 18, 2008EDELMAN JOSEPH-Sell$4.73K
Nov 18, 2008EDELMAN JOSEPH-Sell$64.56K
Nov 18, 2008EDELMAN JOSEPH-Sell$3.48M

Insider Transactions Trends

DateBuySell
2008 Q4-8
2008 Q3--
2008 Q228-
2008 Q1143-
2007 Q46-

XTLB Ownership FAQ

Who Owns XTL Biopharmaceuticals?

XTL Biopharmaceuticals shareholders are primarily institutional investors at 0.03%, followed by 41.29% insiders and 58.68% retail investors. The average institutional ownership in XTL Biopharmaceuticals's industry, Biotech Stocks , is 307.10%, which XTL Biopharmaceuticals falls below.

Who owns the most shares of XTL Biopharmaceuticals?

XTL Biopharmaceuticals’s largest shareholders are Morgan stanley (33.15K shares, 0.61%), Citadel advisors (15.44K shares, 0.28%), and Noked israel (198.89K shares, 0.03%). Together, they hold 0.92% of XTL Biopharmaceuticals’s total shares outstanding.

Does Blackrock own XTL Biopharmaceuticals?

BlackRock is not among the top 10 institutional shareholders of XTL Biopharmaceuticals.

Who is XTL Biopharmaceuticals’s biggest shareholder by percentage of total assets invested?

Noked israel is XTL Biopharmaceuticals’s biggest shareholder by percentage of total assets invested, with 0.04% of its assets in 198.89K XTL Biopharmaceuticals shares, valued at 227K$.

Who is the top mutual fund holder of XTL Biopharmaceuticals shares?

Fidelity Nasdaq Composite Index is the top mutual fund holder of XTL Biopharmaceuticals shares, with 0.10% of its total shares outstanding invested in 8.9K XTL Biopharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools